Denali Therapeutics Inc (NASDAQ:DNLI) COO Alexander O. Schuth sold 7,500 shares of the firm’s stock in a transaction that occurred on Monday, July 8th. The stock was sold at an average price of $20.28, for a total value of $152,100.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

NASDAQ:DNLI opened at $20.22 on Friday. The stock’s 50 day moving average price is $20.00. The company has a current ratio of 11.55, a quick ratio of 11.55 and a debt-to-equity ratio of 0.14. Denali Therapeutics Inc has a 52-week low of $12.32 and a 52-week high of $28.86.

Denali Therapeutics (NASDAQ:DNLI) last released its quarterly earnings results on Wednesday, May 8th. The company reported ($0.41) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.40) by ($0.01). The firm had revenue of $4.21 million for the quarter, compared to analysts’ expectations of $12.88 million. Denali Therapeutics had a negative return on equity of 10.23% and a negative net margin of 38.84%. On average, research analysts expect that Denali Therapeutics Inc will post -1.54 EPS for the current fiscal year.

A number of institutional investors have recently bought and sold shares of DNLI. BlackRock Inc. lifted its position in Denali Therapeutics by 38.3% during the 4th quarter. BlackRock Inc. now owns 4,572,695 shares of the company’s stock worth $94,469,000 after acquiring an additional 1,265,645 shares during the period. Wasatch Advisors Inc. lifted its position in Denali Therapeutics by 1,702.4% during the 1st quarter. Wasatch Advisors Inc. now owns 820,904 shares of the company’s stock worth $19,061,000 after acquiring an additional 775,358 shares during the period. Baillie Gifford & Co. lifted its position in Denali Therapeutics by 13.5% during the 4th quarter. Baillie Gifford & Co. now owns 6,227,724 shares of the company’s stock worth $128,665,000 after acquiring an additional 741,303 shares during the period. Lord Abbett & CO. LLC lifted its position in Denali Therapeutics by 27.8% during the 4th quarter. Lord Abbett & CO. LLC now owns 1,438,608 shares of the company’s stock worth $29,722,000 after acquiring an additional 313,153 shares during the period. Finally, Casdin Capital LLC acquired a new stake in Denali Therapeutics during the 4th quarter worth approximately $2,066,000. 71.69% of the stock is owned by institutional investors.

DNLI has been the topic of a number of research reports. ValuEngine upgraded WPP from a “sell” rating to a “hold” rating in a research note on Wednesday, June 19th. Zacks Investment Research downgraded EXACT Sciences from a “hold” rating to a “sell” rating in a research note on Tuesday, July 2nd. TheStreet upgraded SUMMIT THERAPEU/S from a “d” rating to a “c-” rating in a research note on Thursday, June 13th. Finally, HC Wainwright restated a “buy” rating on shares of ACASTI PHARM-TS in a research note on Wednesday, June 26th. One equities research analyst has rated the stock with a hold rating, three have given a buy rating and one has given a strong buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus target price of $25.50.

About Denali Therapeutics

Denali Therapeutics Inc, a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. The company offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidates, including DNL201 and DNL151, which are in Phase 1 clinical trials for Parkinson's disease.

Recommended Story: Yield Curve

Insider Buying and Selling by Quarter for Denali Therapeutics (NASDAQ:DNLI)

Receive News & Ratings for Denali Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Denali Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.